“With our network of top Ophthalmology investigators and our cutting edge recruitment tactics, WCCT Global is setting the industry standard for conducting and executing phase l Ophthalmology clinical studies.”
Costa Mesa, California (PRWEB) March 14, 2013
WCCT Global, a contract research organization headquartered in Southern California, announced today their overwhelming success in the completion of 4 Cohorts, consisting of 48 Glaucoma subjects, in a developing 60 patient Ophthalmology clinical study. The study protocol called for 60 patients, from multiple population groups, to be randomized with Glaucoma. In less than 4 months WCCT Global quickly recruited and screened 130 patients with Glaucoma and successfully randomized the first 48 participants, meeting all study timelines.
WCCT Global’s continued success in this study is attributed to their extensive network of physicians and their innovative recruitment process. WCCT Global's Chief Operating Officer Jon Rojas stated, “With our network of top Ophthalmology investigators and our cutting edge recruitment tactics, WCCT Global is setting the industry standard for conducting and executing phase I Ophthalmology clinical studies.” This phase l study required randomizing 60 Glaucoma patients in a single site and required 6 overnight stays in less than 4 months. WCCT Global has been an industry leader in ophthalmology phase l clinical studies. Recently WCCT Global completed an overnight ophthalmic phase l trial of 12 Japanese Glaucoma patients as part of a Japanese bridging trial, as well as a half dozen other phase l Glaucoma trials in the last several years. WCCT Global continues to pave the way in research studies for many new developments in Ophthalmology.
More about WCCT Global:
WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.
If your organization would like request how WCCT Global can design your next Ophthalmology clinical study, CLICK HERE.